[The results of SPRINT study from the point of nephrology]

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Optimal systolic blood pressure (SBP) targets for hypertension management in chronic kidney disease (CKD) remain debated.
• High-risk individuals, including those with CKD and mild proteinuria, may benefit from intensive SBP control.

Purpose of the Study:

• To evaluate the impact of intensive SBP control on cardiovascular events and mortality in high-risk individuals.
• To inform nephrologists about the SPRINT trial's implications for managing hypertension in CKD patients.

Main Methods:

• The Systolic Blood Pressure Intervention Trial (SPRINT) was an interventional study.
• Participants included individuals at high risk for cardiovascular events, with some having CKD and mild proteinuria.

Main Results:

• Intensive SBP control (target < 120 mm Hg) significantly reduced major cardiovascular events.
• Overall mortality was also significantly reduced in the intensive treatment group.
• Benefits were observed in high-risk individuals, including those with CKD and mild proteinuria.

Conclusions:

• The SPRINT study provides evidence for intensive SBP control in high-risk patients with CKD.
• Nephrologists should consider SPRINT findings but remain vigilant for adverse events like electrolyte imbalances and acute kidney injury.
• Careful monitoring for adverse effects is crucial when implementing intensive SBP targets in CKD patients.